JP2010513478A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513478A5
JP2010513478A5 JP2009542710A JP2009542710A JP2010513478A5 JP 2010513478 A5 JP2010513478 A5 JP 2010513478A5 JP 2009542710 A JP2009542710 A JP 2009542710A JP 2009542710 A JP2009542710 A JP 2009542710A JP 2010513478 A5 JP2010513478 A5 JP 2010513478A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
indazol
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542710A
Other languages
English (en)
Japanese (ja)
Other versions
JP5119267B2 (ja
JP2010513478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2007/001136 external-priority patent/WO2008076048A1/en
Publication of JP2010513478A publication Critical patent/JP2010513478A/ja
Publication of JP2010513478A5 publication Critical patent/JP2010513478A5/ja
Application granted granted Critical
Publication of JP5119267B2 publication Critical patent/JP5119267B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542710A 2006-12-21 2007-12-20 グルココルチコイド受容体介在障害の処置のためのインダゾリルエステルおよびアミド誘導体 Expired - Fee Related JP5119267B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US87118406P 2006-12-21 2006-12-21
US60/871,184 2006-12-21
US94174507P 2007-06-04 2007-06-04
US60/941,745 2007-06-04
US97852607P 2007-10-09 2007-10-09
US60/978,526 2007-10-09
PCT/SE2007/001136 WO2008076048A1 (en) 2006-12-21 2007-12-20 Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012184346A Division JP2012224647A (ja) 2006-12-21 2012-08-23 グルココルチコイド受容体介在障害の処置のためのインダゾリルエステルおよびアミド誘導体

Publications (3)

Publication Number Publication Date
JP2010513478A JP2010513478A (ja) 2010-04-30
JP2010513478A5 true JP2010513478A5 (cg-RX-API-DMAC7.html) 2012-10-11
JP5119267B2 JP5119267B2 (ja) 2013-01-16

Family

ID=39536557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009542710A Expired - Fee Related JP5119267B2 (ja) 2006-12-21 2007-12-20 グルココルチコイド受容体介在障害の処置のためのインダゾリルエステルおよびアミド誘導体
JP2012184346A Pending JP2012224647A (ja) 2006-12-21 2012-08-23 グルココルチコイド受容体介在障害の処置のためのインダゾリルエステルおよびアミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012184346A Pending JP2012224647A (ja) 2006-12-21 2012-08-23 グルココルチコイド受容体介在障害の処置のためのインダゾリルエステルおよびアミド誘導体

Country Status (36)

Country Link
US (4) US7728030B2 (cg-RX-API-DMAC7.html)
EP (1) EP2102169B1 (cg-RX-API-DMAC7.html)
JP (2) JP5119267B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090091354A (cg-RX-API-DMAC7.html)
CN (1) CN101611015B (cg-RX-API-DMAC7.html)
AR (1) AR064505A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007334659B2 (cg-RX-API-DMAC7.html)
CA (1) CA2673277A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003804A1 (cg-RX-API-DMAC7.html)
CR (1) CR10875A (cg-RX-API-DMAC7.html)
CY (1) CY1113269T1 (cg-RX-API-DMAC7.html)
DK (1) DK2102169T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000148A (cg-RX-API-DMAC7.html)
EA (1) EA016895B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099452A (cg-RX-API-DMAC7.html)
ES (1) ES2387584T3 (cg-RX-API-DMAC7.html)
GT (1) GT200900175A (cg-RX-API-DMAC7.html)
HR (1) HRP20120656T1 (cg-RX-API-DMAC7.html)
IL (1) IL198880A (cg-RX-API-DMAC7.html)
JO (1) JO2754B1 (cg-RX-API-DMAC7.html)
MA (1) MA31087B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009006540A (cg-RX-API-DMAC7.html)
MY (1) MY153270A (cg-RX-API-DMAC7.html)
NO (1) NO20092723L (cg-RX-API-DMAC7.html)
NZ (1) NZ577186A (cg-RX-API-DMAC7.html)
PE (1) PE20081838A1 (cg-RX-API-DMAC7.html)
PL (1) PL2102169T3 (cg-RX-API-DMAC7.html)
PT (1) PT2102169E (cg-RX-API-DMAC7.html)
RS (1) RS52411B (cg-RX-API-DMAC7.html)
SA (1) SA07280740B1 (cg-RX-API-DMAC7.html)
SV (1) SV2009003305A (cg-RX-API-DMAC7.html)
TN (1) TN2009000250A1 (cg-RX-API-DMAC7.html)
TW (1) TWI417094B (cg-RX-API-DMAC7.html)
UY (1) UY30824A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008076048A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903654B (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH081035Y2 (ja) 1993-06-30 1996-01-17 伸夫 高橋 家庭用雑排水の処理装置
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
SA109300309B1 (ar) 2008-05-20 2013-01-22 باير شيرنج فارما ايه جي مشتقات فينيل وبنزو داي أوكسينيل إندازول بها استبدال
WO2009142588A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator
WO2009142568A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a b2-agonist
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
WO2010138421A1 (en) * 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
SG195309A1 (en) 2011-06-29 2013-12-30 Astrazeneca Ab Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
WO2015058026A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015058022A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
US9085564B2 (en) 2013-10-17 2015-07-21 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057426A4 (en) 2013-10-17 2017-03-29 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
KR20160072154A (ko) * 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
KR20160072155A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN106488909A (zh) 2014-07-31 2017-03-08 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
KR20170036677A (ko) 2014-07-31 2017-04-03 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
BR112017000565A2 (pt) 2014-07-31 2017-11-07 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
US9024031B1 (en) 2014-08-19 2015-05-05 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
KR20170058388A (ko) 2014-09-12 2017-05-26 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
FR3026105B1 (fr) * 2014-09-24 2019-04-19 Greenpharma Composition contenant au moins un inhibiteur de certaines chimiokines, son procede d'obtention et son utilisation dermocosmetique ou pharmaceutique
EP3197878B1 (en) * 2014-09-26 2019-07-24 Astrazeneca AB 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
UA120980C2 (uk) * 2015-09-15 2020-03-10 Лео Фарма А/С Нестероїдні модулятори глюкокортикоїдних рецепторів для місцевої доставки ліків
WO2017161518A1 (en) * 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
US10233155B2 (en) 2016-12-29 2019-03-19 Dow Agrosciences Llc Processes for the preparation of pesticide compounds
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
US10626106B2 (en) 2017-12-18 2020-04-21 Gruenenthal Gmbh Substituted pyrrolidine amides I
CN113382990B (zh) 2019-01-11 2024-11-19 格吕伦塔尔有限公司 取代的吡咯烷酰胺iii
WO2020152193A1 (en) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing
WO2020254551A1 (en) 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides iv
WO2020254552A2 (en) 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides v
CN114929684B (zh) * 2019-12-31 2023-08-18 南京明德新药研发有限公司 苯并吡唑类化合物
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor
US20240246985A1 (en) * 2021-06-28 2024-07-25 Medshine Discovery Inc. Crystal form of triazolopyridine-substituted indazole compound and preparation method therefor
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3514696A1 (de) 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3535167A1 (de) 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
TW224462B (cg-RX-API-DMAC7.html) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
CA2114981A1 (en) 1993-02-09 1994-08-10 Kazumi Ogata Quinolonecarboxylic acid derivatives
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
DE69431470T2 (de) 1993-07-26 2003-08-14 Eisai Co., Ltd. Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
AU5772296A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
TW542822B (en) 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
CO4980885A1 (es) 1997-12-29 2000-11-27 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
DE19856475A1 (de) 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
EP1190710A4 (en) 1999-05-13 2003-04-02 Shionogi & Co PREVENTIVE OR THERAPEUTIC MEDICATIONS FOR DIABETES
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
MXPA03002080A (es) 2000-09-11 2003-06-24 Pfizer Prod Inc Derivados de resorcinol.
FR2815030A1 (fr) 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
US20030109550A1 (en) * 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
KR20040058191A (ko) 2001-10-01 2004-07-03 다이쇼 세이야꾸 가부시끼가이샤 Mch 수용체 안타고니스트
IL161940A0 (en) 2001-11-22 2005-11-20 Ono Pharmaceutical Co Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
HRP20040801A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Sulfonylamino derivatives as novel inhibitors of histone deacetylase
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
NL1021182C2 (nl) * 2002-07-30 2004-02-03 Xpar Vision B V Analysesysteem en werkwijze voor het analyseren en controleren van een productieproces voor glasproducten.
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
KR20050036982A (ko) * 2002-08-29 2005-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
CA2515780C (en) 2003-02-20 2012-12-11 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CA2528003A1 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
EP1643960A2 (en) 2003-07-02 2006-04-12 Merck & Co., Inc. Arylsulfonamide derivatives
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
JP4829506B2 (ja) 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
CA2555914A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
SE0402635D0 (sv) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
RS20070076A (sr) * 2004-10-29 2008-09-29 Astrazeneca Ab., Novi derivati sulfonamida kao modulatori glukokortikoidnog receptora za lečenje zapaljenskih bolesti
EP1869003B1 (en) * 2005-04-14 2013-05-15 Glaxo Group Limited Indazoles as glucocorticoid receptor ligands
PE20070112A1 (es) * 2005-06-10 2007-03-08 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
GB0522880D0 (en) 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
WO2007114763A1 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Sulphonamide derivates as modulators of the glucocorticoid receptor
PE20071227A1 (es) 2006-04-20 2008-02-18 Glaxo Group Ltd Compuestos derivados de indazol como moduladores del receptor de glucocorticoides
WO2008008882A2 (en) 2006-07-14 2008-01-17 Eli Lilly And Company Glucocorticoid receptor modulator and methods of use
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
GB0620406D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
US8119681B2 (en) 2006-10-23 2012-02-21 Merck Sharp & Dohme Corp. 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
US8067447B2 (en) 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
MX2009005264A (es) 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
WO2008124665A1 (en) 2007-04-10 2008-10-16 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20100048950A1 (en) 2007-04-10 2010-02-25 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
GB0708858D0 (en) 2007-05-08 2007-06-13 Glaxo Group Ltd Novel compounds
GB0720556D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720544D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720557D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720549D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720546D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0722211D0 (en) 2007-11-12 2007-12-27 Glaxo Group Ltd Novel compounds
GB0724254D0 (en) 2007-12-12 2008-01-23 Glaxo Group Ltd Novel compounds
WO2009108525A2 (en) 2008-02-26 2009-09-03 Merck & Co., Inc. Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators
AU2009220458A1 (en) 2008-03-06 2009-09-11 Merck Sharp & Dohme Corp. Hexahydrocyclopentyl[f]findazole sulfonamides and derivates thereof as selective glucocorticoid receptor modulators
SA109300309B1 (ar) 2008-05-20 2013-01-22 باير شيرنج فارما ايه جي مشتقات فينيل وبنزو داي أوكسينيل إندازول بها استبدال
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist

Similar Documents

Publication Publication Date Title
JP2010513478A5 (cg-RX-API-DMAC7.html)
JP2014515013A5 (cg-RX-API-DMAC7.html)
JP2007302683A5 (cg-RX-API-DMAC7.html)
JP2007514005A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2013525444A5 (cg-RX-API-DMAC7.html)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2013519675A5 (cg-RX-API-DMAC7.html)
JP2015525757A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2014507446A5 (cg-RX-API-DMAC7.html)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2012507535A5 (cg-RX-API-DMAC7.html)
JP2013507408A5 (cg-RX-API-DMAC7.html)
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
IL186374A (en) Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them
JP2009532434A5 (cg-RX-API-DMAC7.html)
JP2010500284A5 (cg-RX-API-DMAC7.html)
IL197783A (en) Polycyclic compounds, preparations containing them and polycyclic compounds for use in the treatment of synthetic respiratory virus infections
JP2016515550A5 (cg-RX-API-DMAC7.html)
JP2019151627A5 (cg-RX-API-DMAC7.html)
JP2012523416A5 (cg-RX-API-DMAC7.html)
JP2008515980A5 (cg-RX-API-DMAC7.html)